<DOC>
	<DOCNO>NCT01254565</DOCNO>
	<brief_summary>The purpose study characterize safety tolerability efficacy multiple ascend dos KAI-4169 hemodialysis subject treatment secondary hyperparathyroidism .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy KAI-4169 Hemodialysis Subjects With Secondary Hyperparathyroidism</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<criteria>Subject provide write informed consent . Intact PTH least 350 pg/mL . Corrected calcium least 9.0 mg/dL . Hemoglobin least 9.0 g/dL . Adequate hemodialysis three time per week . Excepting chronic renal failure , subject judge stable medical condition base medical history , physical examination , routine laboratory test . History symptomatic ventricular dysrhythmias . History angina pectoris congestive heart failure History myocardial infarction , coronary angioplasty , coronary artery bypass graft within past 6 month . History treatment seizure disorder . Recent ( 3 month ) parathyroidectomy . Serum transaminases ( alanine aminotransferase , aspartate aminotransferase ) great two time upper limit normal screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Clinical Trial , Phase 2</keyword>
	<keyword>Renal Dialysis</keyword>
	<keyword>Secondary Hyperparathyroidism</keyword>
	<keyword>Parathyroid hormone</keyword>
</DOC>